title: Preclinical evaluation of131I-Bevacizumab - A prospective agent for radioimmunotherapy in VEGF expressing cancers.
abstract: This study focuses on preparation and evaluation of131I-bevacizumab by Iodogen method for targeting VEGF over-expressing cancers for therapy.131I-Bevacizumab exhibited radiochemical purity of 98.0±0.7%. In vitro stability of131I-Bevacizumab was retained at >85% in both saline and serum at 37°C upto 5 days post iodination. In vitro cell studies showed good immunoreactivity and uptake by VEGF expressing tumor cells. Uptake and retention of131I-Bevacizumab in tumor with reduction in uptake in presence of cold Bevacizumab confirmed its specificity to VEGF.
authors.affiliation: Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India. Electronic address: kmythili@barc.gov.in.
authors.forename: Mythili
authors.initials: M
authors.lastname: Kameswaran
authors.affiliation: Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
authors.forename: Haladhar Dev
authors.initials: HD
authors.lastname: Sarma
authors.affiliation: Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
authors.forename: Ashutosh
authors.initials: A
authors.lastname: Dash
mesh_terms: D000818:Animals; D000074322:Antineoplastic Agents, Immunological / Q000493:pharmacokinetics / Q000627:therapeutic use; D000068258:Bevacizumab / Q000493:pharmacokinetics / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008546:Melanoma, Experimental / Q000378:metabolism / Q000532:radiotherapy; D051379:Mice; D008810:Mice, Inbred C57BL; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use; D014018:Tissue Distribution; D020298:U937 Cells; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D000074322:Antineoplastic Agents, Immunological; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab